Abnormalities of the 11p15 region with overexpression of the normally imprinted insulin-like growth factor II (IGF-II) gene have been implicated in the pathogenesis of adrenocortical tumors. We evaluated the frequency and distribution of 11p15 loss of heterozygosity (LOH) and IGF-II gene overexpression in a series of 82 sporadic adrenocortical tumors, screened for pathological functional imprinting of the 11p15 region in tumors not exhibiting LOH and evaluated the expression of H19 gene in these tumors.
A DRENOCORTICAL carcinomas are rare tumors with poor prognosis. The diagnosis can be difficult. Other than distant metastasis or regional spread, no single finding distinguishes benign from malignant adrenocortical neoplasia (1, 2) . Elucidating the pathogenesis of these tumors might lead to the identification of new prognostic factors. However, the molecular and genetic mechanisms of adrenocortical tumorigenesis and malignant transformation are not well understood. Various oncogenes (such as p53 or gip2) have been proposed to be involved in adrenocortical tumorigenesis. This has not been clearly established for any (3) (4) (5) (6) (7) (8) .
The adrenal gland produces an array of growth factors, including insulin-like growth factor II (IGF-II) (9 -12) . The IGF-II gene maps to the chromosomal 11p15 region, which is subject to parental imprinting. The IGF-II gene is transcribed from the paternal allele (13) (14) (15) . Other genes, H19 and p57 KIP2 , that also map to the 11p15.5 region are imprinted, but unlike the IGF-II gene, it is the maternally derived allele that is active (16 -18) . H19 encodes a ribonucleic acid (RNA) that cannot be translated into a protein (19) and might function as a tumor suppressor gene (20) . p57KIP2 was recently described as a new cyclin-dependent kinase inhibitor, and its gene is a strong candidate suppressor gene (21) . Recently, we showed that loss of the maternal allele with duplication of the paternal allele at the 11p15 locus was frequent in adrenocortical tumors, particularly those that are malignant (22, 23) . This abnormality was frequently associated with a high overexpression of the IGF-II gene. This loss of heterozygosity (LOH) of the 11p15 region had previously been reported in embryonic tumors, including Wilms' tumor, the most frequent tumor of the predisposing Beckwith-Wiedemann syndrome (see Refs. 24 and 25 for reviews). More recently, pathological functional imprinting with biallelic expression of the IGF-II gene was shown in Wilms' tumors that had not lost heterozygosity at 11p (14, 15) . In this model, relaxation of maternal allele was often associated with abrogation of H19 gene expression (26, 27) . Deletion of the maternal H19 gene region in mice results in maternal IGF-II gene expression and in a growth advantage in mice inheriting the abnormal H19 gene from their mother (28) . Thus, H19 could control the imprinting (and thus the expression) of the IGF-II gene.
Expression of both H19 and IGF-II genes is up-regulated by ACTH in human fetal adrenals (29) . Abrogation of H19 gene expression was described in a few sporadic adrenocortical carcinomas, which also exhibited overexpression of the IGF-II gene (30) . The details of the effect of 11p15 dysregu-lation on tumor proliferation are unknown, but it appears to be associated with the malignant phenotype. There is evidence that IGF-II is an important autocrine growth factor (31) (32) (33) (34) . Recently, studies on uterine (35) , lung (36) , and testicular (37) tumors provided evidence that IGF-II genomic imprinting is relaxed not only in childhood tumors, but also in malignant adulthood tumors.
The aims of this study were to evaluate the frequency and distribution of 11p15 region abnormalities and IGF-II gene overexpression in a large series of well documented sporadic adrenocortical tumors and to assess the prognostic value of these molecular markers. To determine whether pathological functional imprinting is an earlier event in adrenocortical tumorigenesis, we tested for pathological functional imprinting of the 11p15 region in adrenocortical tumors exhibiting no or only partial (mosaicism) LOH.
Our data showed that abnormalities of the 11p15 region are late events associated with the transition from the benign to the malignant state. H19 expression status depends on the activity of the maternal allele, but does not always negatively correlate with the expression of the IGF-II gene.
These data show that dysregulation of the 11p15 region is a major event during adrenocortical tumorigenesis.
Subjects and Methods Patients
Eighty-two adults, 16 -82 yr old (13 men and 69 women) with sporadic adrenocortical tumors were included in the study between 1989 -1996. None of them had features of any tumor-predisposing syndrome (Beckwith-Wiedemann, McCune-Albright, multiple endocrine neoplasia type 1, or Li-Fraumeni syndromes).
Hormonal status and the stage of the tumor as localized, regional, or metastatic were evaluated as previously described (38) . Histological features, including high mitotic rate, atypical mitoses, high nuclear grade, low percentage of clear cells, necrosis, diffuse architecture of tumor, capsular invasion, sinusoidal invasion, and venous invasion were carefully gathered. Tumors without any of these histological features were classified as benign. Localized tumors with one to three of these histological features were classified as suspect. Tumors with more than three of these features or with documentation of metastasis or recurrence were classified as malignant tumors (2, 39) . Pathological and hormonal data are summarized in Table 1 .
Thirty-five patients were diagnosed as having localized adrenocortical tumors (weight, 8 -56 g) with a strictly benign histological appearance. Two presented with bilateral adenomas. Most (91.5%) had secreting tumors.
Eighteen patients were diagnosed as having suspect tumors (weight, 12-240 g), 14 of which were hormonally active.
Twenty-nine patients were initially diagnosed as having adrenocortical carcinomas (9 with metastases, 1 with local recurrence, 8 with regional invasion, and 11 with localized disease but histological data suggestive of malignancy). Eighty percent had secreting tumors. Tumors weights varied between 69 -5000 g. For 1 patient with metastases, the primary adrenocortical tumor, metastatic, and adjacent nontumor liver samples were available. For another patient with metastases, only a lung metastasis sample was available for study.
Tissue fragments obtained at surgery were immediately frozen in liquid nitrogen and stored at Ϫ80 C until DNA and RNA extraction. Control leukocyte DNA for reference was available for all patients.
Isolation of nucleic acids
Isolation of nucleic acids was performed as previously described (22) .
Southern blot analysis
Search for allelic losses at the 11p13-15 region. Allelic loss of the 11p13-15 region in tumors was investigated by Southern blot analysis using six human genomic or complementary DNA (cDNA) probes (insulin, IGF-II, H19, H-ras-1, catalase, and calcitonin) (22) . Restriction endonucleases were chosen on the basis of the polymorphism of their digestion patterns: TaqI for insulin, H19, catalase, H-ras-1, and calcitonin probes, and AvaII for the IGF-II probe. The restriction pattern of tumor DNA was in all cases compared to the leukocyte DNA restriction pattern.
Parental analysis. The IGF-II probe was used for parental analysis. This probe is a 663-bp EcoRI fragment of the IGF-II cDNA (40) that recognizes an AvaII polymorphism near the 5Ј-part of exon 9 of the IGF-II gene ( Fig.  1) . In normal tissues, the 5Ј-part of exon 9 of the maternal allele of the IGF-II gene is specifically hypomethylated and thus completely disappears when digested with AvaII and the methylation-sensitive enzyme HpaII; the paternal allele is hypermethylated and is thus not further digested by HpaII (Fig. 1, A 
and B) (41).

IGF-II and H19 messenger RNA (mRNA) in tumors
Tumor RNA contents were evaluated by dot blot and Northern blot analyses as previously described (22) . Normal control adrenal RNA was obtained from glands surgically removed during large nephrectomy for kidney cancer. Placenta, which contains large amounts of IGF-II and H19 mRNA, was used as a positive control.
Hybridization signals were measured by densitometric analysis using a GS700 imaging densitometer and the molecular analyst data system (Bio-Rad, Richmond, CA). Each IGF-II and H19 mRNA signal was normalized to that for human ␤-actin probe (Clontech, Palo Alto, CA).
Reverse transcription-PCR for analyzing allele-specific expression of the IGF-II gene
An ApaI-AvaII polymorphism in the 3Ј-untranslated region of the IGF-II gene (Fig. 1A ) was used to analyze allele-specific expression (42) . RNA samples (250 ng) were treated with deoxyribonuclease (DNase) to eliminate any DNA contamination, reverse transcribed at 70 C, and subsequently amplified using a thermostable DNA polymerase (PerkinElmer, Norwalk, CT) (43) . Sense and antisense primers were, respectively, 5Ј-CTTGGACTTTGAGTCAAATTGG-3Ј (S1) and 5Ј-GGTCGT-GCCAATTACATTTCA-3Ј (AS1; Fig. 1A ) (36) . The cycle, which consisted of denaturation for 1 min at 94 C, annealing for 2 min at 55 C, and extension for 3 min at 72 C, was repeated 35 times. PCR products were digested separately with ApaI or AvaII. ApaI cleaves 1 of the polymorphic alleles, and AvaII cleaves the other; therefore, spurious interpretation due to partial digestion could be excluded. Control leukocyte and tumor DNA samples were amplified in parallel, and their GC, Glucocorticoid secretion; GC ϩ A, glucocorticoid and androgen secretions; A, androgen secretion; E, estrogen secretion; MC, mineralocorticoid precursor secretion; NS, nonsecreting. restriction patterns were compared to the cDNA pattern. DNase-treated RNA PCR products were used as a control for DNA contamination of the RNA samples. Products of amplification and digestion were analyzed by electrophoresis on a 3% Metaphor XR agarose gel (FMC Bioproducts, Rockland, ME).
Results
Structural analysis at the 11p13-15 locus
All patients were informative for one or more of the 11p13-15 markers, as detected by Southern blot analysis.
Thirty-eight tumors (46.3%) exhibited LOH, whereas all leukocyte DNA gave normal heterozygous profiles (Figs. 1B  and 2, A and B) . Allelic loss varied according to pathological data: 3 of 35 (8.6%) in benign tumors, 11 of 18 (61.1%) in suspect localized tumors, and 24 of 29 (82.8%) in malignant tumors (Fig. 3A and Table 2 ).
Southern blot patterns of the 38 tumors with LOH were evaluated by densitometry. Twenty-eight tumors showed the complete loss of 1 allele and 2 copies of the remaining allele ( Fig. 2A, patient 29 , as an example). Ten tumors gave mosaic patterns with allelic disproportion; in these 10 tumors the percentage of cells with LOH (44) varied between 12-59% ( Fig. 2A, patient 55) .
Allele-specific methylation was investigated using the AvaII with or without HpaII/IGF-II system in 15 patients. This parental analysis showed that the lost allele was of maternal origin, and the duplicated allele was of paternal origin in all (Fig. 2B, patient 72 ) except 1 patient with mosaicism who had partially lost the paternal allele (Fig. 2B,  patient 35 ).
Functional analysis of the IGF-II gene
IGF-II mRNA expression in adrenocortical tumors. IGF-II mRNA was measured by dot blot and Northern blot analyses. High levels of IGF-II mRNA (between 10 -582 times that in normal human adult adrenocortical tissue) were found in 38 of 82 (46.3%) adrenocortical tumors. The distribution of overexpression among the 3 groups of tumors was similar to that of 11p15 LOH: 0% (0 of 35), 72.2% (13 of 18), and 86.2% (25 of 29) in benign, suspect, and malignant tumors, respectively (Table 3 and Fig. 3, A and B) .
The expression of the IGF-II gene in the other 44 tumors was between 0.3-2.2 times (mean Ϯ sd, 1.1 Ϯ 0.74) that observed in normal human adult adrenocortical tissue.
The distribution of IGF-II mRNA content according to pathological group is shown in Fig. 4A .
Parental imprinting of the IGF-II gene.
Parental imprinting of the IGF-II gene could be investigated by reverse transcription-PCR analysis in 13 of the 37 tumors with normal IGF-II gene expression and without LOH (11 benign, 1 suspect, and 1 malignant tumors). All had monoallelic paternal expression of the IGF-II gene (Fig. 5A, patient 80 , as an example of benign tumor) as normal adrenal tissue (Fig. 5A ).
Among tumors with abnormalities of 11p15 region (LOH and/or IGF-II gene overexpression; n ϭ 45), 31 of them exhibited both. Twelve (including 2 of 7 mosaicisms) were informative for the ApaI-AvaII/IGF-II polymorphism. The pattern of parental expression of the IGF-II gene showed a loss of imprinting in the 2 informative mosaicisms with expression of the 2 parental alleles in the tumor contingent cell not undergoing LOH (Fig. 5A, patient 35) . The other tumors (with complete LOH) expressed the remaining paternal allele (Fig. 5A, patient 29) .
Seven of tumors with abnormalities of 11p15 region showed LOH with normal IGF-II mRNA content (0.25-2.18). One of the three patients with mosaicism was informative for the ApaI-AvaII/IGF-II polymorphism and showed monoallelic paternal expression (Fig. 5A, patient 10) .
Finally, seven tumors with abnormalities of 11p15 region exhibited strong overexpression of the IGF-II gene without LOH. Two were informative for the ApaI-AvaII/IGF-II polymorphism; one had a loss of imprinting with expression of the two parental alleles (Fig. 5A, patient 47 ), and the other had normal paternal monoallelic expression of the IGF-II gene (Fig. 5A, patient 76) .
H19 mRNA expression in adrenocortical tumors
H19 mRNA was studied in 55 tumors and was found to be variable according to pathological groups (Fig. 4B and Table  3 ); however, abrogation of H19 expression was found in some suspect and in most malignant tumors.
In tumors without abnormalities of the 11p15 region, H19 gene expression (n ϭ 23) was always detectable and varied from 0.15-11.7 times that in normal adrenal tissue (Fig. 5, B and C).
In tumors with LOH, whatever the IGF-II mRNA content [high (n ϭ 21) or normal (n ϭ 5)], H19 expression was low (Ͻ10% the expression of normal adrenal tissue for 22 of them), consistent with loss of the functional maternal H19 gene (Fig. 5, B and C) .
In tumors with overexpression of the IGF-II gene and without LOH, H19 expression (n ϭ 6) was variable (Fig. 5 , B and C). It was undetectable in two of the six tumors (including the tumor with biallelic expression of the IGF-II gene) and was between 2.85-8.1 that in normal adrenal tissue in the remaining tumors (including the tumor with paternal monoallelic expression of the IGF-II gene).
Thus, H19 expression only depends on the activity of the maternal allele, and abrogation of H19 expression appears to be a final common pathway of both LOH and pathological functional imprinting.
H19 expression was not always abrogated when IGF-II was overexpressed.
Discussion
Adrenocortical tumors are poorly characterized. Benign and malignant adrenocortical tumors are usually distinguished by consideration of clinical, hormonal, and gross and microscopic pathological features (2, 45) , and borderline cases should be rigorously followed-up. A recent study reported the diagnostic usefulness of HLA class II antigene expression in the assessment of adrenocortical tumors (46) . Elucidating the molecular mechanisms of adrenocortical tu- Percentages are given in parentheses. mor formation might lead to the development of prognostic tools. This series of 82 patients is interesting for 2 major reasons: it is the largest series reporting pathological and molecular analyses of adrenocortical tumors, and the clinical, hormonal, and pathological characteristics of the patients are well documented. Careful pathological evaluation identifies a group of 18 patients, referred to as the suspect group, with uncertain prognosis that will require a long and rigorous follow-up. We previously reported LOH (loss of maternal allele and duplication of paternal allele) of the imprinted 11p15 region and increased IGF-II gene expression in adrenocortical carcinomas (22, 23) . We now report on the frequency and distribution of 11p15 LOH and IGF-II gene overexpression in this large series of cases to assess their prognostic value. We also investigated whether pathological functional imprinting was an event before LOH during adrenocortical tumorigenesis and assessed the expression of two key genes of the 11p15 region, the H19 and the IGF-II genes.
Clonal analysis had previously suggested that adrenocortical tumorigenesis may be a multistep process with sequential progression from the normal to the adenomatous and then to the malignant cell (47, 48) . The most obvious finding of this study is that 11p15 LOH and high IGF-II expression are events associated with the transition from the benign to the malignant state. Indeed, LOH and/or IGF-II gene overexpression were found in 27 of the 29 malignant tumors (93.1%) and in only 3 of the 35 benign tumors (8.6%). The high frequency (83.3%) of these abnormalities in tumors classified as suspect suggests that these tumors could have been brought into a malignant phenotype. In tumors weighing about 50 -200 g, which are often difficult to diagnose, the incidence of 11p15 abnormalities was high. These data suggest that tumors with such abnormalities should be regarded as malignant tumors. A prospective study of the outcome of these patients will allow us to strictly assert the prognostic value of these markers.
The second important finding concerns the pathogenetic approach. In tumors without LOH and without overexpression of the IGF-II gene (mainly benign tumors), no pathological functional imprinting was found. These data agree with previous studies; loss of imprinting of the IGF-II gene was described in other adulthood tumors (including uterine, lung, and testicular tumors), but exclusively in malignant ones (35) (36) (37) .
We demonstrated that tumors with a mosaic pattern for LOH and overexpression of IGF-II gene exhibited pathological functional imprinting in the tumor cells not undergoing allelic loss at 11p15. In these tumors two different molecular mechanisms have been identified that both contribute to IGF-II overexpression: pathological imprinting and loss of the maternal allele. In a sequential scenario occurring in the same tumor cell, pathological imprinting must be the first event. Yet because we found only a few tumors with pathological imprinting and without LOH, these two events must be temporally very close. Maintenance of parental imprinting is linked to methylation status (26, 27) , and changes in DNA methylation have been associated with chromatin alterations that could lead to genetic instability in cancer cells (49) . Thus, pathological imprinting of the 11p15 region might predispose to allelic loss.
Previous studies on the Wilms' tumor model showed that only 30% of tumors had 11p15 allelic loss and that 70% of the remaining tumors exhibited pathological imprinting of the 11p15 region, which is presumably an alternative mechanism to LOH to induce IGF-II overexpression (14, 15) . It has been shown that deletion of the maternal H19 gene promoter allows expression of the normally restrained maternal IGF-II gene and results in a growth advantage (28) . The abrogation of the H19 gene expression in Wilms' tumor (by deletion or pathological imprinting of the maternal allele) could explain the overexpression of the IGF-II gene in Wilms' tumors (26, 27) . Loss of H19 expression was also described in some hormonally active adrenocortical carcinomas (30) . Retained H19 expression in tumors without abnormality of the 11p15 region and loss of H19 expression in tumors with IGF-II gene overexpression and LOH are consistent with the control of IGF-II expression by H19 or with a local circuit linking IGF-II and H19 via enhancer competition. However, two observations concerning other tumors suggest that factors other than H19 control IGF-II expression: 1) 20% of the tumors showing LOH and abrogation of H19 expression had normal IGF-II expression; and 2) tumors without LOH or pathological imprinting, but with IGF-II gene overexpression, had normal to high H19 expression.
H19 and IGF-II genes use the same cis-acting regulatory elements (50) , and the competition between the two genes is based upon differential DNA methylation between the maternal and the paternal chromosomes (51) . The absence of overexpression of the IGF-II gene in 20% of the tumors undergoing LOH could be due to a demethylation of the remaining paternal allele in tumors. However, there was no clear difference in allele-specific methylation of exon 9 between tumors overexpressing and tumors not overexpressing the IGF-II gene (data not shown). This suggests that a factor(s) other than methylation participates in the control of IGF-II expression.
Mitogenic activities of IGF-II have been clearly established in various models of overgrowth disorders, including the Beckwith-Wiedemann syndrome, as well as nonsyndromic somatic overgrowth, exhibiting abnormal methylation of the H19 gene and relaxation of IGF-II imprinting in various tissues (52) . A central role for IGF-II in tumorigenesis is also supported by a mouse model in which focal activation of IGF-II in the pancreas appeared to be responsible for the development of pancreatic carcinoma (32, 33) . Moreover, in the Wilms' tumor model, IGF-II has been recently shown to play a crucial role in tumor growth through the type 1 IGF receptor (31) .
Whatever the mechanisms of IGF-II overexpression (LOH, pathological functional imprinting, or others), it appears with the transition from the benign to the malignant phenotype. Thus, IGF-II overexpression and the associated abnormalities at the 11p15 locus must now be used for diagnostic evaluation of adrenocortical tumors.
